Abstract
OBJECTIVE: This retrospective research was designed to compare the treatment outcomes of H-type hypertension (HTH) patients treated with Amlodipine Besylate-Folic Acid Tablets (Amlo-FA) vs. Enalapril Maleate-Folic Acid Tablets (Ena-FA). METHODS: This investigation comprised 155 HTH cases. The control group was treated with the Ena-FA regimen, while the observation group received Amlo-FA therapy. Patients' clinical data were comparatively analyzed. RESULTS: Compared to controls, the observation group demonstrated superior overall treatment effectiveness (90.48% vs. 71.83%, P=0.003). Following treatment, systolic blood pressure (SBP; (129.86±6.24) mmHg vs. (139.66±8.04) mmHg, P<0.001), diastolic blood pressure (DBP; (80.26±7.46) mmHg vs. (89.00±9.68) mmHg, P<0.001), homocysteine (Hcy; (13.06±3.18) μmol/L vs. (19.39±3.37) μmol/L, P<0.001), carotid intima-media thickness (CIMT; (1.11±0.28) mm vs. (1.29±0.27) mm, P<0.001), fasting blood glucose (FPG; (5.74±1.68) mmol/L vs. (6.40±2.02) mmol/L, P=0.028), glycosylated hemoglobin (HbA1c; (5.85±1.85)% vs. (6.93±1.90)%, P<0.001), urinary albumin-to-creatinine ratio (UACR; (53.64±15.44) mg/L vs. (74.17±16.96) mg/L, P<0.001), total cholesterol (TC; (4.92±1.61) mmol/L vs. (6.42±1.63) mmol/L, P<0.001), TG (triglycerides; (1.66±0.72) mmol/L vs. (2.44±0.68) mmol/L, P<0.001), and low-density lipoprotein cholesterol (LDL-C; (2.35±0.70) mmol/L vs. (2.99±0.84) mmol/L, P<0.001) were markedly reduced in the observation cohort relative to the control group outcomes. Conversely, high-density lipoprotein cholesterol (HDL-C; (1.78±0.69) mmol/L vs. (1.47±0.50) mmol/L, P=0.002), Medication Adherence Self-Efficacy Scale (MASES; (89.31±8.87) score vs. (79.70±7.61) score, P<0.001), and the 8-item Morisky Medication Adherence Scale (MMAS-8; 5.00 (3.00, 6.00) score vs. 6.00 (4.00, 7.00) score, P<0.001) scores showed a significant increase under the same comparisons. The overall side effect profile was significantly more favorable in the observation group (5.95% vs. 16.90%, P=0.030). No significant inter-group differences were observed in the incidence of various individual and total adverse cardiovascular and cerebrovascular events (4.76% vs. 12.68%, P>0.05). Finally, comorbid diabetes (B=1.447, OR=4.250, P=0.010) and treatment methods (B=-1.196, OR=0.303, P=0.013) were factors independently influencing patients' curative effects. CONCLUSION: Amlo-FA is effective in treating HTH.